What's Behind The Jump In Corcept Therapeutics Stock?

Benzinga03-26

The FDA approved relacorilant in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622008723?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/25/Crude-Oil-Price-Hike-Graph-Chart--Stock-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-26 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622008723","market":"hk","top_or_hot":-1,"title":"What's Behind The Jump In Corcept Therapeutics Stock?","media":"Benzinga","content":"<div>\n<p>The FDA approved relacorilant in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Behind The Jump In Corcept Therapeutics Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Behind The Jump In Corcept Therapeutics Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 00:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA approved relacorilant in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock","article_id":"2622008723","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/25/Crude-Oil-Price-Hike-Graph-Chart--Stock-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51461646/whats-behind-the-jump-in-corcept-therapeutics-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622008723","pubTimestamp":1774454760,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","PFS":"Provident Financial Services Inc","LU0566484027.USD":"安本美国小盘成长股","CORT":"Corcept医疗","BK4097":"系统软件","BK4195":"互助储蓄与抵押信贷金融服务","BK4532":"文艺复兴科技持仓","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药"},"translate_title":"Corcept Therapeutics股价上涨的背后是什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1.5,"PFS":1,"OS":1},"content_text":"The FDA approved relacorilant in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.\nThe efficacy of the relacorilant treatment was assessed in a multicenter, open-label trial involving 381 patients. The results showed promising progression-free survival (PFS) and overall survival (OS) rates, with the PFS at 6.5 months and OS at 16 months for patients treated with the relacorilant and nab-paclitaxel combination. \nThe positive updates appears to be driving increased investor confidence in Corcept on Wednesday, with shares hitting $50 before pulling back slightly.\nCorcept is trading 28.2% above its 20-day SMA, but it remains 20.8% below its 100-day SMA, showing strong short-term recovery attempts inside a still-damaged longer-term trend. Shares are down 24.91% over the past 12 months, and the stock is positioned closer to its 52-week low than its high.\nRSI is at 44.39, which sits in neutral territory and suggests the surge hasn't pushed momentum into an overheated condition based on this reading. Meanwhile, MACD is at -1.5742 versus a signal line of -2.0436, a bullish configuration that points to improving upside momentum.\nRSI in the 30–50 range with bullish MACD indicates momentum leaning bullish.\nLooking further out, the next major catalyst for the stock arrives with the May 4, 2026 (estimated) earnings report.\nAnalyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $92.50. Recent analyst moves include:\nCORT Stock Price Activity: Corcept Therapeutics shares were up 27.88% at $43.25 at the time of publication on Wednesday, according to Benzinga Pro data.\nImage: Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622008723","isCrawlerRequest":true}